Modern medicine hasn’t made big strides in managing psychiatric disorders, a growing challenge with global implications. “The treatment of psychiatric disorders hasn’t changed from what it was like 30 years ago, medications are given by trial and error and we don’t really know what’s going to work,” Amit Etkin, CEO of Alto Neuroscience, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. BI senior health-care associate Jean Rivera Irizarry joins Dr. Etkin for an in-depth interview about Alto, how it was formed, its drug-selection process and how the company aims to redefine the way we treat such disorders.

Modern medicine hasn’t made big strides in managing psychiatric disorders, a growing challenge with global implications. “The treatment of psychiatric disorders hasn’t changed from what it was like 30 years ago, medications are given by trial and error and we don’t really know what’s going to work,” Amit Etkin, CEO of Alto Neuroscience, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. BI senior health-care associate Jean Rivera Irizarry joins Dr. Etkin for an in-depth interview about Alto, how it was formed, its drug-selection process and how the company aims to redefine the way we treat such disorders.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Alto Is Aiming to Redefine Psychiatry

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/98756993-8e55-4171-8210-b17200c9c003/transcript

EDAP can treat prostate cancer by focusing ultrasound waves at just the target region, similar to how a magnify glass can focus light from the sun so intensely that it can burn a piece of paper, allowing it to eliminate the cancer while limiting side effects, CEO Ryan Rhodes explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Rhodes sits down with BI analyst Matt Henriksson to talk about his path from Intuitive Surgical to lead EDAP, how the Focal One robot uses high intensity focused ultrasound, or HIFU, to ablate prostate cancer without needing an incision or removing the whole prostate and how the HIFI Study shows that Focal One can be a viable alternative to radical prostatectomy.

EDAP can treat prostate cancer by focusing ultrasound waves at just the target region, similar to how a magnify glass can focus light from the sun so intensely that it can burn a piece of paper, allowing it to eliminate the cancer while limiting side effects, CEO Ryan Rhodes explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Rhodes sits down with BI analyst Matt Henriksson to talk about his path from Intuitive Surgical to lead EDAP, how the Focal One robot uses high intensity focused ultrasound, or HIFU, to ablate prostate cancer without needing an incision or removing the whole prostate and how the HIFI Study shows that Focal One can be a viable alternative to radical prostatectomy.

EDAP’s Robot Treats Prostate Cancer

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6b78f3a8-6ea3-427e-915d-b19501188758/transcript

Haemonetics, a medical-device maker that focuses on markets including blood and plasma collection, is evolving to expand broadly with more diversification and greater sustainability over time, all with the view that good products win, CEO Chris Simon explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simon sits down with BI analyst Matt Henriksson to talk about Haemonetics and how its has built out its hospital franchise with M&A to include high-growth segments that diversifies the company beyond its traditional blood and plasma collection businesses. He also shares his views on how medtech companies need to have products with competitive advantages as the hospital environment rationalizes and whittles down the number of medtech suppliers they use.

Haemonetics, a medical-device maker that focuses on markets including blood and plasma collection, is evolving to expand broadly with more diversification and greater sustainability over time, all with the view that good products win, CEO Chris Simon explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simon sits down with BI analyst Matt Henriksson to talk about Haemonetics and how its has built out its hospital franchise with M&amp;A to include high-growth segments that diversifies the company beyond its traditional blood and plasma collection businesses. He also shares his views on how medtech companies need to have products with competitive advantages as the hospital environment rationalizes and whittles down the number of medtech suppliers they use.

Haemonetics Diversifies Into New Form

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/427158b9-8617-41c9-a98b-b18e00ca2b1a/transcript

OrthoPediatrics’ aspiration is to develop anatomically appropriate implants, instruments and specialized braces for children, so surgeons don’t need to “MacGyver” their way with treating a child with adult sized devices, CEO David Bailey explains to Bloomberg Intelligence, referring to the multi-skilled character from the 1980s TV series. In this Vanguards of Health Care podcast episode, Bailey sits down with BI analyst Matt Henriksson for an in-depth interview to talk about OrthoPediatrics, how its technology built a cohesive commercial model to aid pediatric orthopedic surgeons, including products and clinical support, and how it has developed a strong M&A platform to add innovation to its portfolio.

OrthoPediatrics’ aspiration is to develop anatomically appropriate implants, instruments and specialized braces for children, so surgeons don’t need to “MacGyver” their way with treating a child with adult sized devices, CEO David Bailey explains to Bloomberg Intelligence, referring to the multi-skilled character from the 1980s TV series. In this Vanguards of Health Care podcast episode, Bailey sits down with BI analyst Matt Henriksson for an in-depth interview to talk about OrthoPediatrics, how its technology built a cohesive commercial model to aid pediatric orthopedic surgeons, including products and clinical support, and how it has developed a strong M&amp;A platform to add innovation to its portfolio.

OrthoPediatrics’ Focus on Helping Kids

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/5b41c5a7-8994-4f97-948d-b18700d75842/transcript

Alto Is Aiming to Redefine Psychiatry

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips